Comparison of Three Chemotherapy Regimens in Elderly Patients with Diffuse Large B Cell Lymphoma: Experience at a Single National Reference Center in Mexico

Table 4

Cox regression analysis of disease-free survival (DFS).

Variable	HR	IC 95%	value
Univariate analysis
Treatment
RCHOP	—
RChOP	1.380	0.442–4.302	0.578
RCOP	2.131	0.714–6.356	0.175
Infections
None	—
Ambulatory treated	0.761	0.315–1.838	0.545
Required hospitalization	3.152	1.457–6.819	0.004
Febrile neutropenia	4.481	2.222–9.035	0.000
Hb mg/dL
>13	—
10–12.9	1.555	0.854–2.831	0.148
8–10	1.669	0.398–6.999	0.484
<8	3.206	1.324–7.762	0.010
IPI
Low	—
Low-intermediate	1.721	0.598–4.954	0.314
High-intermediate	2.737	1.020–7.342	0.045
High	2.705	1.009–7.252	0.048
Cycles of treatment	0.661	0.589–0.740	0.000
B symptoms
Yes	2.099	1.140–3.863	0.017
Albumin (g/dL)	0.427	0.285–0.641	0.000
ECOG
2	2.328	1.282–4.227	0.005
3	3.900	1.767–8.605	0.001
LDH
Increased	1.891	1.093–3.270	0.023
Creatinine (mg/dL)	1.965	1.130–3.415	0.017
Age	—	—	—
<75 years	—	—	—
≥75 years	1.2	0.703–2.048	0.503
B2M microglobulin	1.211	1.077–1.361	0.001
Leucocytes	1.0001	1.00005–1.0002	0.002
Multivariate analysis
Treatment
RCHOP	—
RChOP	1.339	0.416–4.303	0.624
RCOP	11.967	2.781–51.483	0.001
Infections
None	—
Ambulatory treated	0.848	0.327–2.198	0.736
Required hospitalization	2.459	0.970–6.237	0.058
Febrile neutropenia	2.650	1.135–6.189	0.024
HB mg/dL
>13
10–12.9	2.008	1.053–3.827	0.034
8–10	2.121	0.468–9.606	0.329
<8	2.509	0.874–7.201	0.087
IPI
Low	—
Low-intermediate	3.397	1.011–11.414	0.048
High-intermediate	9.612	2.952–31.293	0.000
High	9.411	2.946–30.069	0.000
Cycles of treatment	0.558	0.470–0.6625	0.000